17:16 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

MabVax reports Phase I data for cancer candidate MVT-1075

MabVax Therapeutics Holdings Inc. (NASDAQ:MBVX) reported interim data from three patients with CA19.9-positive malignancies in the first cohort of a Phase I trial showing that MVT-1075 was well tolerated and accumulated on target lesions as...
23:28 , Nov 30, 2017 |  BC Week In Review  |  Clinical News

Berg reports Phase II data for ubidecarenone in metastatic pancreatic cancer

In September, Berg LLC (Framingham, Mass.) reported data from 5 evaluable patients with advanced pancreatic cancer in a Phase II trial showing that second-line treatment with IV ubidecarenone (Coenzyme Q10; BPM 31510) alone or in...
17:50 , Nov 2, 2017 |  BC Innovations  |  Product R&D

Sweet specificity

Siamab Therapeutics Inc. is gearing up to compete in the small but active space of companies targeting sugar groups that are up-regulated in cancer. So far, its technology has produced a lead therapeutic, a deal...
20:46 , Jul 7, 2017 |  BC Week In Review  |  Clinical News

MabVax begins Phase I of MVT-1075 in CA19.9-positive cancers

MabVax Therapeutics Holdings Inc. (NASDAQ:MBVX) began an open-label, U.S. Phase I trial to evaluate escalating doses of MVT-1075 in about 22 patients with relapsed or refractory pancreatic cancer and other CA19.9-positive cancers who have failed...
19:55 , Jun 9, 2017 |  BC Week In Review  |  Clinical News

MabVax reports Phase Ia data for MVT-5873 in pancreatic cancer

MabVax Therapeutics Holdings Inc. (NASDAQ:MBVX) reported data from 32 evaluable patients with locally advanced or metastatic pancreatic cancer in an open-label, dose-escalation, U.S. Phase Ia trial showing that IV MVT-5873 (5B1 antibody, HuMab-5B1) led to...
07:00 , Oct 17, 2016 |  BioCentury  |  Product Development

Yes we PanCAN

A major goal of a new multidrug platform study organized by the Pancreatic Cancer Action Network is to meet patients' needs better than traditional trials do. Among other things, that means accepting patients who have...
07:00 , Jun 29, 2015 |  BC Week In Review  |  Clinical News

Nanoplatin: Phase III ongoing

NanoCarrier said it submitted an IND in Japan to add Japanese patients to an ongoing, open-label, Asian Phase III trial comparing 90 mg/m 2 IV Nanoplatin given every 3 weeks plus gemcitabine vs. gemcitabine alone...
07:00 , Oct 20, 2014 |  BC Week In Review  |  Clinical News

Necuparanib: Phase I/II data

Top-line data from 12 evaluable patients with advanced metastatic pancreatic cancer in the open-label, dose-escalation, U.S. Part A of a Phase I/II trial showed that once-daily oral necuparanib plus Abraxane nab-paclitaxel and gemcitabine led...
07:00 , Apr 15, 2013 |  BioCentury  |  Emerging Company Profile

Abcodia: Banking on biomarkers

Abcodia Ltd. is using blood samples that have been taken annually by the U.K. Collaborative Trial for Ovarian Cancer Screening to identify serum biomarkers that can detect breast, lung, pancreatic and colorectal tumors at least...
07:00 , Jul 19, 2010 |  BC Week In Review  |  Clinical News

Amplimexon imexon: Phase II data

In the double-blind, U.S. Phase II AMP-019 trial in 142 patients, Amplimexon plus Gemzar gemcitabine missed the primary endpoint of significantly improving OS vs. placebo plus Gemzar (p=0.64). AmpliMed said the trial required a...